Abingdon Health

Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization

Retrieved on: 
Friday, July 9, 2021
Medical specialties, Virology, Medicine, Health, COVID-19, Occupational safety and health, Public health, Zoonoses, Spike protein, COVID-19 vaccines, CIGA Healthcare, Abingdon Health

Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.

Key Points: 
  • Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.
  • "The development of the VITROS Anti-SARS-CoV-2 IgG Quantitative Test shows Ortho's leadership in response to the need for standardization of SARS-CoV-2 serological methods currently used," said Ivan Salgo, MD, head of medical, clinical, and scientific affairs, Ortho Clinical Diagnostics.
  • "Ortho's quantitative COVID-19 IgG antibody test, which targets the spike protein, is an important tool to help health care and policy teams to understand long-term antibody responses to SARS-CoV-2."
  • The VITROS COVID-19 antibody tests include IgG and Total tests that target the S1 spike protein, and a Total test that targets the nucleocapsid protein.

Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization

Retrieved on: 
Friday, July 9, 2021
Medical specialties, Virology, Medicine, Health, COVID-19, Occupational safety and health, Public health, Zoonoses, Spike protein, COVID-19 vaccines, CIGA Healthcare, Abingdon Health

Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.

Key Points: 
  • Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2.
  • "The development of the VITROS Anti-SARS-CoV-2 IgG Quantitative Test shows Ortho's leadership in response to the need for standardization of SARS-CoV-2 serological methods currently used," said Ivan Salgo, MD, head of medical, clinical, and scientific affairs, Ortho Clinical Diagnostics.
  • "Ortho's quantitative COVID-19 IgG antibody test, which targets the spike protein, is an important tool to help health care and policy teams to understand long-term antibody responses to SARS-CoV-2."
  • The VITROS COVID-19 antibody tests include IgG and Total tests that target the S1 spike protein, and a Total test that targets the nucleocapsid protein.

AbC-19™ Rapid Test used in UK BioBank COVID-19 Antibody Study

Retrieved on: 
Monday, March 29, 2021
Medicine, AbC-19 rapid antibody test, Health, Abingdon Health, Biological databases, Articles, UK Rapid Test Consortium, UK Biobank, COVID-19

York, U.K. 29 March 2021: The UK-RTC is pleased to announce that the AbC-19 rapid neutralising antibody test is being deployed in Phase 2 of the UK Biobank Coronavirus self-test antibody study.

Key Points: 
  • York, U.K. 29 March 2021: The UK-RTC is pleased to announce that the AbC-19 rapid neutralising antibody test is being deployed in Phase 2 of the UK Biobank Coronavirus self-test antibody study.
  • The AbC-19 Rapid Test is being utilised in Phase 2 of the study, which initiated in March 2021.
  • Further details of the study can be found on the UK BioBank website .
  • The test has been developed by the UK Rapid Test Consortium(UK-RTC)of which Abingdon Health is the lead member.

Abingdon Health Plc signs distribution agreement with BioSure UK

Retrieved on: 
Wednesday, March 10, 2021
Medicine, Clinical medicine, Abingdon Health, Lateral flow test, Medical tests, Health care, Rapid antigen test, AbC-19 rapid antibody test

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19.

Key Points: 
  • Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19.
  • Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing.
  • Founded in 2008, Abingdon Health is headquartered in York, England.
  • Since launching in 2015, theBioSUREHIVSelf Testhas helped people throughout the UK and the world, to #knowyourstatus.

AbC-19™ Rapid Test Available for Purchase by Healthcare Professionals

Retrieved on: 
Tuesday, February 16, 2021
Infectious diseases, Biotechnology, Health, Medical devices, Medicine, Medical tests, Immunologic tests, Medical terminology, AbC-19 rapid antibody test, Abingdon Health, Rapid diagnostic test, Immunoassay, Rapid antigen test, COVID-19 testing

Abingdon Health plc (the Company), a leading international developer and manufacturer of high quality and effective rapid tests, announces that the AbC-19 Rapid Test for the detection of SARS-CoV-2 antibodies is now available for purchase by healthcare professionals on the Abingdon Health website .

Key Points: 
  • Abingdon Health plc (the Company), a leading international developer and manufacturer of high quality and effective rapid tests, announces that the AbC-19 Rapid Test for the detection of SARS-CoV-2 antibodies is now available for purchase by healthcare professionals on the Abingdon Health website .
  • View the full release here: https://www.businesswire.com/news/home/20210216005611/en/
    The AbC-19 Rapid Test Process (Graphic: Business Wire)
    The AbC-19 Rapid Test is a self-contained, highly accurate lateral flow immunoassay designed to give results within 20 minutes at the point of use.
  • The AbC-19 Rapid Test has demonstrated high levels of sensitivity and specificity in a clinical setting.
  • Please note AbC-19 Rapid Test is available for professional use only and not for self-testing.

Abingdon Health signs collaboration and co-marketing agreement with Abcam

Retrieved on: 
Tuesday, February 9, 2021
Abcam, Immunologic tests, Abingdon Health, Lateral flow test, Abingdon, Colloidal gold, Companies of the United Kingdom, Medicine, Health care

York, and Cambridge U.K. 09 February 2021: Abingdon Health (AIM:ABDX) (Abingdon or the Company), a leading international developer and manufacturer of high quality and effective rapid tests, has signed a collaboration and co-marketing agreement with Abcam plc (NASDAQ:ABCM; AIM:ABC) (Abcam), a global leader in the supply of life science research tools and reagents.

Key Points: 
  • York, and Cambridge U.K. 09 February 2021: Abingdon Health (AIM:ABDX) (Abingdon or the Company), a leading international developer and manufacturer of high quality and effective rapid tests, has signed a collaboration and co-marketing agreement with Abcam plc (NASDAQ:ABCM; AIM:ABC) (Abcam), a global leader in the supply of life science research tools and reagents.
  • Under the terms of the agreement, Abcam will be the preferred supplier to Abingdon of gold nanoparticles and custom conjugation reagents and services, for the Companys lateral flow assays.
  • We also look forward to working with Abcam to identify and service their customers lateral flow contract development and manufacturing requirements.
  • Mennah Moustafa, Abcams VP of Business Development, commented We are excited to be collaborating with Abingdon Health to provide critical components for their lateral flow tests.